Minimal Residual Disease Testing Market Size Report 2032: Market Trends, Challenges, and Opportunities in Next-Gen Clinical Research

DelveInsight's Minimal Residual Disease Testing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Minimal Residual Disease Testing Companies market shares, challenges, Minimal Residual Disease Testing Market Drivers, barriers, trends, and key market Minimal Residual Disease Testing companies in the market.

To read more about the latest highlights related to the Minimal Residual Disease Testing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Minimal Residual Disease Testing Market Report
• In June 2025, QIAGEN expanded its minimal residual disease (MRD) testing portfolio through new strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics. These collaborations aim to strengthen QIAGEN's presence in MRD testing for both solid tumors and blood cancers.
• In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two key solutions. The first, Labcorp Plasma Detect, is designed to help assess the risk of disease recurrence in patients with stage III colon cancer. The second, PGDx elioTM plasma focus Dx, is the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, aimed at identifying patients who may benefit from targeted therapies.
• In January 2025, Adaptive Biotechnologies Corporation announced a multi-year exclusive strategic commercial collaboration aimed at advancing MRD monitoring for patients with select blood cancers. The partnership combines Adaptive's clonoSEQ® MRD test with NeoGenomics' COMPASS and CHART assessment services, providing clinicians and patients with deeper insights throughout the treatment journey.
• The minimal residual disease testing market was valued at USD 2,031.45 million in 2024, growing at a CAGR of 10.61% during the forecast period from 2025 to 2032 to reach USD 4,514.74 million by 2032.
• North America is projected to hold the largest share of the Minimal Residual Disease Testing market in 2024, driven by several key factors.
• The leading Minimal Residual Disease Testing Companies such as F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others.

To know more about why North America is leading the market growth in the Minimal Residual Disease Testing Market, get a snapshot @ Minimal Residual Disease Testing Market Outlook- https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Minimal Residual Disease Testing Market Dynamics
According to data from the International Agency for Research on Cancer (2022), in 2022, an estimated 487,294 new cases of leukemia were reported globally, with projections indicating a rise to 746,019 cases by 2045. Despite successful treatment, small amounts of leukemic cells can persist in the body, remaining undetectable by conventional diagnostic methods and increasing the risk of relapse. Minimal Residual Disease (MRD) testing addresses this critical gap by detecting even trace levels of cancer cells with high sensitivity, enabling timely clinical intervention. This is particularly vital in aggressive subtypes such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), where MRD status is a key prognostic marker, thereby contributing significantly to the growth of the MRD testing market.

Minimal Residual Disease Testing Market Segmentation Analysis
Minimal Residual Disease Testing Market by Test Type (Polymerase Chain Reaction, Flow Cytometry, Next Generation Sequencing, and Others), Application (Leukemia, Lymphoma, Solid Tumors, and Others), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Research Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Get a sneak peek at the Minimal Residual Disease Testing Market Dynamics @ Minimal Residual Disease Testing Market Dynamics Analysis- https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Minimal Residual Disease Testing Companies
F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others.

Minimal Residual Disease Testing Market Drivers
The demand for minimal residual disease (MRD) testing is primarily fueled by the rising incidence of solid tumors and hematologic malignancies such as leukemia, multiple myeloma, and lymphoma. Advancements in molecular diagnostic technologies have significantly enhanced the accuracy of MRD detection, with the increasing product development and launch activities by key market players continue to strengthen market dynamics. Collectively, these factors are expected to drive robust and sustained growth in the MRD testing market throughout the forecast period from 2025 to 2032.

Which MedTech key players in the Minimal Residual Disease Testing Market are set to emerge as the trendsetter explore @ Minimal Residual Disease Testing Companies- https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Minimal Residual Disease Testing Market Report
• Coverage- Global
• Forecast Period- 2025-2032
• Minimal Residual Disease Testing Companies- F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others.

Interested in knowing the Minimal Residual Disease Testing Market by 2032? Click to get a snapshot of the Minimal Residual Disease Testing Market Trends- https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Minimal Residual Disease Testing Market Report Introduction
2. Minimal Residual Disease Testing Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Minimal Residual Disease Testing Market Key Factors Analysis
6. Minimal Residual Disease Testing Market Porter's Five Forces Analysis
7. Minimal Residual Disease Testing Market Assessment
8. Minimal Residual Disease Testing Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.